Author presents a bullish case for Novo Nordisk based on European pension fund shifts, insulin market dominance, and weight loss trends, recommending holding for at least 3 years.
NVO — LONG The author argues Novo Nordisk is a buy and hold for at least 3 years due to three main reasons: European pension funds shifting investments from US to European stocks will benefit Novo; Novo controls about 50% of world insulin supply with diabetes type 2 expected to increase 46% by 2050; and the weight loss trend is here to stay with room for multiple competitors. Short-term headwinds include competition from Eli Lilly and potential drug price regulation, but these are dwarfed by the long-term trends.
Novo Nordisk still controls about 50% of the world's insulin supply. Diabetes type 2 is expected to increase 46% by 2050.
This Reddit post, published January 27, 2026, features u/Correct_Fall_5484 discussing NVO. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/Correct_Fall_5484 · Tickers: NVO